Clinical trialEarly Phase 1Unknown
68Ga-FAPI-FS PET/CT and PET/MR in Pancreatic Cancer
Preliminary Study of 68Ga-FAPI-FS PET/CT in Patients With Pancreatic Cancer
- Outcome
- Outcome unknown
- Phase
- Early Phase 1
- Status
- Unknown
- Study type
- Interventional
- Start
- 1 June 2022
- Listed end
- 1 June 2024
- Enrollment
- 50 participants
- Sites
- 1
- Primary outcomes
- Adverse events after injection of 68Ga-FAPI-FS
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 25 May 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a preliminary study of 68Ga-FAPI-FS PET/CT or PET/MR in patients with confirmed or suspicious pancreatic cancer. The goal is to determine the safety, biodistribution, and tumor uptake of 68Ga-FAPI-FS.
Detailed description public domain (ClinicalTrials.gov)
This is a preliminary phase 0 study in patients with confirmed or suspicious pancreatic cancer. Each patient will receive one dose of 68Ga-FAPI-FS by intravenous route. Dedicated whole-body PET/CT imaging will be performed. A comparative 18F-FDG PET/CT will also be performed within a week.